Federal Register / Vol. 65, No. 14 / Friday, January 21, 2000 / Notices 3467

a single entity (i.e., molecule) having the

desired functionality of all of its

constituent molecules. Frequently, one

of the constituent molecules of a

chimeric molecule is a ‘‘targeting

molecule’’. The targeting molecule is a

molecule such as a ligand or an

antibody that specifically binds to its

corresponding target, for example a

receptor on a cell surface. Thus, for

example, where the targeting molecule

is an antibody, the chimeric molecule

will specifically bind (target) cells and

tissues bearing the epitope to which the

antibody is directed.

Another constituent of the chimeric

molecule may be an ‘‘effector

molecule’’. The effector molecule refers

to a molecule that is to be specifically

transported to the target to which the

chimeric molecule is specifically

directed. The effector molecule typically

has a characteristic activity that is

desired to be delivered to the target cell.

Effector molecules include cytotoxins,

labels, radionuclides, other ligands,

drugs, prodrugs, liposome, etc. In

particular, where the effector

component is a cytotoxin, the chimeric

molecule may act as a potent cell-killing

agent specifically targeting the cytotoxin

to cells bearing a particular target

molecule. For example, chimeric fusion

protein which include interleukin–4

(‘‘IL–4’’) or transforming growth factor

(RGFα’’) fused to Pseudomonas

exotoxin (‘‘PE’’) or interleukin–2 (‘‘IL–

2’’) fused to Diphtheria toxin (‘‘DT’’)

have been shown to specifically target

and kill cancer cells.

Generally, it is desirable to increase

specificity and affinity and decrease

cross-reactivity of chimeric cytotoxins

with targets to be spared in order to

increase their efficacy. To the extent a

chimeric modecule preferentially selects

and binds to its target (e.g., a tumor cell)

and not to a non-target (e.g., a healthy

cell), side effects of the chimeric

molecule will be minimized.

Unfortunately, many targets to which

chimeric cytotoxins have been directed

(e.g., the IL–2 receptor), while showing

elevated expression on tumor cells, are

also expressed to some extent, and often

at significant levels, on healthy cells.

Thus, chimeric cytotoxins directed to

these targets frequently show adverse

side-effects as they bind non-target (e.g.,

healthy) cells that also express the

targeted receptor.

Technology

The technology disclosed in the 08/

706,207 patent application is directed to

a method and compositions to deliver

an effector molecule to tumor cell.

Specifically the technology relates to a

chimeric molecule that specifically

binds to IL–13 receptors which when

combined with a blocker reagent (e.g.,

interleukin–4, an interleukin–4

antagonist, an interleukin–4 receptor

binding antibody etc.) specifically

delivers receptor directed cytotoxins to

tumors over expressing IL–13 receptors

without causing undesired cytotoxicity

to normal cells. This is because a variety

of human cancer cells including brain

tumors, kidney tumors, and AIDSassociated Kaposi’s tumors etc. over

express private IL–13 receptors and

normal cells express low levels of

shared IL–13 receptors with IL–4

receptors. IL–13 cytotoxin remains very

cytotoxic to cancel cells in the presence

of IL–4 receptor blocker agents while

cytotoxicity and undesired side effects

of cytotoxin administration are

prevented in normal cells. This

approach provides unique specificity of

delivering IL–13 receptor directed

cytotoxic agents to cancer cells.

The above mentioned Invention is

available for licensing.

Dated: January 12, 2000.

Jack Spiegel, Ph.D.,

Director, Division of Technology Development

& Transfer, Office of Technology Transfer.

[FR Doc. 00–1424 Filed 1–20–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is

owned by an agency of the U.S.

Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

ADDRESSES: Licensing information and

a copy of the U.S. patent application

referenced below may be obtained by

contacting J.E. Fahner-Vihtelic at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; Telephone: 301/

496–7735 ext. 270; Fax: 301/402–0220;

E-mail; jf36z@nih.gov. A signed

Confidential Disclosure Agreement is

required to receive a copy of any patent

application.

Artificial Salivary Gland

Bruce J. Baum et al. (NIDCR)

Serial No. 60/121,335

Filed 24 Feb 1999

The present application describes an

artificial fluid secreting prosthetic

device for non-invasive insertion and

methods of using this device.

Specifically, compositions and methods

based on the discovery of an artificial

fluid secreting prosthesis are disclosed

in this application. Currently, there is

no conventional effective treatment for

salivary gland hypofunction. And

although the transplantation of

mammalian salivary glands has also

been tried, this option has not proven

desirable due to lack of sufficient donor

supplies. To date, the inventors have

performed experiments that have

demonstrated: (1) Subjects having

irradiated salivary gland cells can be

induced to secrete fluid subsequent to

transfer of a gene; (2) heterologous genes

can be transferred to salivary gland

cells; and (3) an artificial gland has been

designed having a support, an

attachment surface joined to the

support, and a monolayer of allogenic

cells, engineered to secrete ions and

water unidirectionally, joined to the

attachment surface.

Dated: January 11, 2000.

Jack Spiegel, Ph.D.,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 00–1425 Filed 1–20–00;8:45am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel

Mentored Clinical Scientist Development

Award.

Date: February 7–8, 2000.

3468 Federal Register / Vol. 65, No. 14 / Friday, January 21, 2000 / Notices

Time: 8:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant

applications.

Place: Chevy Chase Holiday Inn, 5520

Wisconsin Ave., Chevy Chase, MD 20815.

Contact Person: Eric H. Brown, Scientific

Review Administrator, NIH, NHLBI, DEA,

Rockledge Building II, 6701 Rockledge Drive,

Suite 7204, Bethesda, MD 20892–7924, (301)

435–0299, browne@gwgate.nhlbi.nih.gov.

Name of Committee: National Heart Lung,

and Blood Institute Special Emphasis Panel

Demonstration and Education Research Grant

Applicants.

Date: February 24, 2000.

Time: 9:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant

applications.

Place: Hilton National Airport Hotel, 2399

Jefferson Davis Highway, Arlington, VA

22202.

Contact Person: Louise P. Corman,

Scientific Review Administrator, Review

Branch, NIH, NHLBI, Rockledge Building II,

6701 Rockledge Drive, Suite 7180, Bethesda,

MD 20892–7924, (301) 435–0270..

(Catalogue of Federal Domestic Assistance

Programs Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research; 93.838, Lung

Diseases Research; 93.839, Blood Diseases

and Resources Research, National Institutes

of Health, HHS)

Dated: January 11, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–1415 Filed 1–20–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Deafness and

Other Communication Disorders;

Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: Communication

Disorders Review Committee.

Date: March 1–2, 2000.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant

applications.

Place: Latham Hotel, 3000 M Street, NW.,

Washington, DC 20007–3701.

Contact Person: Melissa Stick, Scientific

Review Administrator, Scientific Review

Branch, Division of Extramural Research,

NIDCD/NIH, 6120 Executive Blvd., Bethesda,

MD 20892, 301–496–8683.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.173, Biological Research

Related to Deafness and Communicative

Disorders, National Institutes of Health, HHS)

Dated: January 13, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–1412 Filed 1–20–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse

and Alcoholism; Notice of Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

National Advisory Council on Alcohol

Abuse and Alcoholism.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications

and/or contract proposals and the

discussions could disclose confidential

trade secrets or commercial property

such as patentable material, and person

information concerning individuals

associated with the grant applications

and/or contract proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

Name of Committee: National Advisory

Council on Alcohol Abuse and Alcoholism.

Date: February 9–10, 2000.

Closed: February 9, 2000, 7:00 PM to 9:00

PM.

Agenda: To review and evaluate grant

applications.

Place: Bethesda Marriott Hotel, 5151 Pooks

Hill Road, Bethesda, MD 20814.

Closed: February 10, 2000, 8:15 AM to 9:00

AM.

Agenda: To review and evaluate grant

applications.

Place: Natcher Building, 45 Center Drive,

Conference Rooms E1/E2, Bethesda, MD

20892.

Open: February 10, 2000, 9:00 AM to 3:00

PM.

Agenda: Program documents.

Place: Natcher Building, 45 Center Drive,

Conference Rooms E1/E2, Bethesda, MD

20892.

Contact Person: James F. Vaughan,

Executive Secretary, National Institute on

Alcohol Abuse and Alcoholism, National

Institutes of Health, PHS, DHHS, Bethesda,

MD 20892.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.271, Alcohol Research

Career Development Awards for Scientists

and Clinicians; 93.272, Alcohol National

Research Service Awards for Research

Training; 93.273, Alcohol Research Programs;

93.891, Alcohol Research Center Grants,

National Institutes of Health, HHS)

Dated: January 13, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–1413 Filed 1–20–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Environmental

Health Sciences; Notice of Closed

Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee:

National Institute of Environmental

Health Sciences Special Emphasis Panel

Hazardous Materials Worker Health and

Safety Training (RFA–99–009).

Date: February 22–24, 2000.

Time: 7:00 PM to 5:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Hawthorn Suites Hotel, 300

Meredith Drive, Durham, NC 27713.

Contact Person: Michael A. Oxman,

Scientific Review Administrator, NIEHS,